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Abstract 
Introduction Clinical research is vital in the discovery of new medical knowledge and reducing disease 
risk in humans. In clinical research poor data quality is one of the major problems, affecting data integrity 
and the generalisability of the research findings. To achieve high quality data, guidance needs to be 
provided to clinical studies on the collection, processing and handling of data. However, clinical trials are 
implementing ad hoc, pragmatic approaches to ensure data quality. This study aims to explore the 
procedures for ensuring data quality in Australian clinical research studies. Material and methods We 
conducted a national cross-sectional, mixed-mode multi-contact (postal letter and e-mail) web-based 
survey of clinical researchers associated with clinical studies listed on the Australian and New Zealand 
Clinical Trials Registry. Results Of the 3689 clinical studies contacted, 589 (16%) responded, 570 (97%) 
consented and 441 (77%) completed the survey. 67% clinical studies reported following national and/or 
international guidelines for data monitoring, with the National Statement (86%) and Good Clinical Practice 
Guidelines (55%) most common. Source data were most likely to be recorded on one instrument (46%), of 
which paper (77%) being most common. 46.4% studies did not use data management software and 55% 
monitored data via traditional approaches (e.g. source data verification). Training on data quality was only 
provided to less than half of the staff responsible for data entry (43.9%) and data monitoring (37.5%). 
Regression analysis on 179 (33%) respondents found a borderline significant association between 
intervention trials and a definition for protocol deviation and/or violation (odds 3.065, p = 0.096). This may 
suggest when clinical trials are provided with additional guidance and resources, they are more likely to 
implement required procedures. Statistical strength of the full regression model was not significant χ2 
(13, 179) = 15.827, p = 0.259. Conclusion Small single-site academic clinical studies implemented ad hoc 
procedures to ensure data quality. Education and training are required to promote standardised practices 
to ensure data quality in small scale clinical trials. 
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Abstract   
Introduction: Clinical research is vital in the discovery of new medical knowledge and reducing 
disease risk in humans. In clinical research poor data quality is one of the major problems, affecting 
data integrity and the generalisability of the research findings. To achieve high quality data, 
guidance needs to be provided to clinical studies on the collection, processing and handling of data. 
However, clinical trials are implementing ad hoc, pragmatic approaches to ensure data quality. This 
study aims to explore the procedures for ensuring data quality in Australian clinical research 
studies. 
Material and methods: We conducted a national cross-sectional, mixed-mode multi-contact 
(postal letter and e-mail) web-based survey of clinical researchers associated with clinical studies 
listed on the Australian and New Zealand Clinical Trials Registry.  
Results: Of the 3689 clinical studies contacted, 589 (16%) responded, 570 (97%) consented and 
441 (77%) completed the survey. 67% clinical studies reported following national and/or 
international guidelines for data monitoring, with the National Statement (86%) and Good Clinical 
Practice Guidelines (55%) most common. Source data were most likely to be recorded on one 
instrument (46%), of which paper (77%) being most common. 46.4% studies did not use data 
management software and 55% monitored data via traditional approaches (e.g. source data 
verification). Training on data quality was only provided to less than half of the staff responsible for 
data entry (43.9%) and data monitoring (37.5%). Regression analysis on 179 (33%) respondents 
found a borderline significant association between intervention trials and a definition for protocol 
deviation and/or violation (odds 3.065, p=0.096). This may suggest when clinical trials are provided 
with additional guidance and resources, they are more likely to implement required procedures. 
Statistical strength of the full regression model was not significant χ2 (13, 179) = 15.827, p=0.259.  
Conclusion: Small single-site academic clinical studies implemented ad hoc procedures to ensure 
data quality. Education and training are required to promote standardised practices to ensure data 
quality in small scale clinical trials.  
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Clinical research is vital in the discovery of new treatments, prevention, diagnosis/screening and 
reducing the risk of disease in humans[1]. In clinical research poor data quality is one of the major 
problems, seriously affecting data integrity and the generalisability of the research findings[2, 3]. 
Therefore, minimising poor quality data is crucial for clinical research to produce accurate and 
reliable evidence to improve patient care. Best practice to ensure data quality is preventing errors 
from happening rather than retrospectively finding and fixing errors[4]. To achieve this, guidance 
can be provided to clinical research studies on the collection, processing and handling of data. 
However, previous research identifies current international and national clinical data quality 
guidelines lack uniformity creating confusion within the research community[5]. Thus, there is a 
need to ensure clinical research is carried out in accordance with standardised procedures that meet 
known quality guidelines.  
 
The International Conference on Harmonization (ICH) guideline for Good Clinical Practice (GCP) 
E6(R2) is an ethical and scientific quality standard for designing, conducting, recording and 
reporting trials that involve human participants[6]. The guideline states, “quality control should be 
applied to each stage of data handling to ensure that all data are reliable and have been processed 
correctly” [pg.22]. These guidelines are not specific about the amount of monitoring needed to 
ensure quality and give flexibility in their interpretation[7, 8]. Concerns regarding broad guidelines 
were identified amongst clinical research centres responding to a survey of data quality 
management in Europe[9]. The three key findings of this survey are: firstly, heterogeneity in data 
management exists; secondly, freely available clinical data management guidelines are limited; and 
thirdly, 50% of centres did not comply with guidelines, including GCP for independent validation 
by an external auditor[9]. It is evident that a standardised, more specific approach needs to be 
adopted for monitoring data quality in clinical research. In accordance with this notion, a survey 
conducted by the Clinical Trials Transformation Initiative (CTTI) in the United States also found 
that there is heterogeneity within and between organizational monitoring practices across academic 
government, clinical research organizations and industry[10]. This has led to a quest by many 
researchers for new avenues to monitor data quality in clinical research settings.  
 
The importance of data quality is well established within the clinical research community[5, 11, 12] 
and the need for training has been identified[13-15]. For instance, providing training and 
implementing testing to all key clinical trial staff in GCP, protocols and standard operating 
procedures (SOPs) is vital for improving the clinical research process[16]. Unfortunately, only a 
few data management training programs have been proposed and are specific to the nursing 
 
 
literature[17, 18]. Recently, Read[19] published a case study that highlighted a workshop training 
series to educate clinical researchers on best practice with data management, including core 
competencies in data quality maintenance. However, none of these programs explicitly emphasize 
the importance of monitoring to ensure data quality. In an effort to overcome the lack of evidence, 
further empirical research is needed to identify standardised guidelines for clinical research data 
quality monitoring and relevant training programs.  
 
Our initial study identified developing and maintaining data management is a challenge for clinical 
trials[5]. We found clinical trials implemented ad hoc, pragmatic approaches to ensure data quality 
and only 50% reported having a data management plan. Thus, the current study aimed to explore in 
more detail, the procedures that are implemented for ensuring data quality in Australian clinical 
studies. We defined the objective to acquire an improved understanding from clinical researchers on 
how data is defined, collected, processed and handled, and any education and training related to 
data quality in this process. This will lead to a new body of knowledge upon which to develop a 
data quality monitoring framework.  
 
2. Material and Methods 
2.1. Planning 
A mixed mode multi-contact national survey design was implemented to achieve high responses by 
ensuring broad contact with the target population and providing them with the opportunity to 
respond. In order to reduce total survey error, all four sources of error (coverage, sampling, non-
response and measurement error) were simultaneously controlled by applying a tailored holistic 
approach informed by the principles proposed by Dillman et al.[20]. Social exchange theory was 
applied to decrease cost, establish trust and increase the benefits for survey respondents[21-23]. 
Overall, the survey design was tailored to the population (clinical researchers), situation (Australia) 
and topic (data quality).  
 
2.2. Setting 
Clinical studies listed on the Australian and New Zealand Clinical Trials Registry (ANZCTR)[24] 
as of 1st March 2018 were invited to participate in a cross-sectional survey. The ANZCTR database 
is an online registry of clinical studies being undertaken in Australia, New Zealand and elsewhere. 
An advance search of the ANZCTR database was completed with the following inclusion criteria: 
intervention and observation trials; randomised and non-randomised trials; recruitment status either 
‘recruiting’ or ‘active, not recruiting’; all gender; all age groups; ethics approved; both healthy and 
non-healthy volunteers; and recruitment country being Australia. Persons listed on the ANZCTR 
 
 
registry as the contact for scientific queries for each clinical study were asked to complete the 
survey. Sampling error was reduced by inviting all clinical studies that met the inclusion criteria. 
However, as it is not a legal requirement for clinical studies in Australia to be listed on the registry, 
it is inevitable to miss those not on the registry. 
 
To avoid the potential risk of bias, clinical studies with affiliation to the University of Wollongong 
(UoW), the organisation where the researchers were employed, were excluded from the study. Also 
excluded were clinical studies with international contact details so as to minimise the influence of 
different national regulations/guidelines for conducting data monitoring. Those who did not wish to 
participate were provided with an option to withdraw and provide an optional reason. Informed tacit 
consent was given by completion of the online survey questionnaire form. Ethics approval was 
obtained from the UoW Human Research Ethics Committee (HE16/131). 
 
2.3. Question design and development  
The design and development of the survey followed the Checklist for Reporting Results of Internet 
E-Surveys (CHERRIES)[25, 26]. A 46 item self-administed semi-quantitative closed survey design 
was developed and informed by our feasibility study[5]. Adaptive questioning was applied to 14 
items branching the total number of questions depending on individual survey responses. Answers 
to all items were voluntary. Respondents were provided with the option to skip or leave question 
items blank, or choose non-responses, such as “not applicable” or “don’t know”. 
 
The survey included seven sections: respondent demographics, clinical study demographics, data 
definition, data collection, data processing, data representation and education and training. REDCap 
(Research Electronic Data Capture), a secure, web-based application designed to support data 
capture for research studies[27], was used to design the survey, collect and manage data. Construct 
validation, including wording, structure, order and grouping of questions were evaluated by a 
convenience sample of three UoW researchers. Once consensus on the design of questions was 
reached further feedback was sought through think-aloud cognitive interviews[28] with five UoW 
clinical researchers and based on two types of theories. First, how individuals respond to survey 
questions was based on the psychological perspective promoted by the Cognitive Aspects of Survey 
Methodology (CASM) viewpoint by Tourangeau’s four-stage cognitive model[29]. Second, the 
cognitive interview as a means to test survey questions (methodology) was based on Ericsson and 
Simon’s think-aloud interview theoretical basis[30, 31]. The cognitive interviews used a descriptive 
approach[32] and aimed to reduce measurement error by gaining a better understanding of how 
respondents understand and interpret the survey items, visual design, presentation and navigation 
 
 
problems. Participation in the face-to-face audio recorded interview was voluntary and each 
participant returned a signed consent form prior to commencing the interview.  
 
2.4. Survey administration  
The web-based survey in order to reduce coverage error, contacted respondents via two modes of 
communication, postal delivery and e-mail, which Millar and Dillman[33] suggest can encourage 
responses. The initial postal letter was sent on 26th March 2018 and followed by three e-mail 
reminders over an 11-week period. The postal letter contained a link to the REDCap online survey 
login and included an individual access code. The email reminders included a personal Uniform 
Resource Locator (URL) link that allowed the respondent to automatically log into the survey for 
convenience. To increase the likelihood of responses and simultaneously reduce nonresponse error 
multiple contact attempts were made which varied in contact timing. Each clinical study was 
provided with a de-identified participant code to ensure anonymity. Respondents using their unique 
survey code and/or URL were able to log back into the survey to review and edit items prior to final 
submission and survey closing date. If surveys were incomplete the most recent data entry was 
saved for data analysis. 
 
2.5. Data analysis 
Incomplete surveys were included in the analysis to respect all respondents’ contributions and 
reduce the bias of topic salience. Data was analysed with IBM SPSS software (IBM Corp. Released 
2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). Descriptive 
statistics summarised the characteristics of respondents, clinical study demographics and the 
aggregated responses to survey items. For ‘select all that apply’ survey items the multiple response 
set was used in SPSS using a dichotomies scale. Free text responses were analysed using deductive 
content analysis[34]. 
 
Univariate analysis was performed to determine the potential association between data quality 
monitoring variables and clinical study type using chi-square analysis. Any independent variables 
(predictors) which achieved significance at p<0.2[35] were considered for inclusion in the 
multivariate analysis. The dependent variable was an intervention (clinical) trial or not (i.e. an 
observational study). All covariates included in the model are listed in Table 4. The cross-sectional 
associations between clinical study demographics, data collection setting and data quality 
monitoring procedures and those classified as an intervention (clinical) trial were analysed using 
three methods - forced entry, forward and backward likelihood ratio (LR) stepwise - logistic 
regression (p<0.05). This decision was made in accordance with the recommendations for data 
 
 
analysis and research without precedence, i.e., to base a hypothesis for testing[36, 37]. Forced entry 
method is the preferred method[38], forward and backward stepwise logistic regression are reported 
in Supplementary data 5 and Supplementary data 6 respectively.  In all three methods, the 
dependent variable and the independent variables (met the p<0.2 criteria) (see footnote Table 4; 
Supplementary data 5, Table 1; and Supplementary data 6, Table 1) that were considered were 
identical. The probability for the forwards stepwise method was set at 0.5 and the backwards 
stepwise method set at 0.1[36, 37]. Survey responses ‘not applicable’ and ‘don’t know’ were coded 
as missing and removed from the regression analysis. The survey question, ‘Does the clinical study 
involve staff in developing case report forms (CRF)s?’ was exempt from this; instead, ‘not 
applicable’ answers were included considering the possibility of a student, volunteer and/or single 
project lead/person developed the CRFs. 
 
3. Results 
Initial postal letter invitations were sent to 3845 of the 3999 clinical studies identified in the 
ANZCTR registry (Figure 1). 146 respondents could not be contacted as the postal letter was 
returned to the sender (RTS) and all three follow-up messages were bounced back with an error 
message. Therefore, only 3689 respondents received the invitation to complete the survey. 589 
viewed the initial survey page (16% view rate). 570 agreed to participate (96.8% participation rate). 
Only 547 responses were included in analysis as 23 empty responses were excluded. Finally, 441 
responses were complete (77.4% completion rate). Survey respondents were more likely to be 
female, have a doctoral degree, employed for a duration of 0-4 years and on a continuing 
appointment (Table 1). The deidentified data set (n=547) and the instructions for access have been 
made public at https://github.com/lah993/DQ_national_survey in accordance with the Creative 




Figure 1: Survey invitation flow diagram.   
 
 
Table 1: Survey respondents’ demographic characteristics (n=547). 
Characteristics n (%) 
Gender Female 332 (60.7) 
Male 206 (37.7) 
Prefer not to disclose 6 (1.1) 
Prefer to self-describe 1 (0.2) 
Missing  2 (0.4) 
Highest level of 
education 
Doctoral degree 347 (63.4) 
Masters/Postgraduate degree 115 (21.0) 
Bachelor degree (including Honours) 84 (15.4) 
Did not complete high school 1 (0.2) 




nearest half year 
0-4 157 (28.7) 
5-9.9 140 (25.6) 
10-14.9 102 (18.6) 
15-24.9 93 (17.0) 
25+ 35 (6.4) 
Missing  20 (3.7) 
Appointment 
(current job or 
position)  
Student 23 (4.2) 
Casual 13 (2.4) 
Continuing 292 (53.4) 
Visiting / Honorary Fellow 15 (2.7) 
Fixed-term contract, nearest half yeara (years) 198 (36.2) 
 <1  25 (12.6) 
 1-1.9 66 (33.3) 
 2-2.9 17 (8.6) 
 3-3.9 22 (11.1) 
 4-4.9 24 (12.1) 
 ≥5  44 (22.2) 
  Missing  0 (0) 
 Missing 6 (1.1) 
a specified time or ascertainable period 
 
Characteristics of the clinical studies described by the survey respondents are provided in Table 2. 
The majority of survey respondents were associated with clinical studies that were administered 
from academic (university) organisations, were an interventional clinical trial, phase IV and single-
site. Further, clinical studies mostly collected data from hospital setting, targeted 100-499 




Table 2: Survey respondents associated clinical study demographic characteristics (n=547).  
Characteristics 
n (%) 
Percent of Cases 
(%) 
Organisation that 
administers the studya,b  
Academic (university) 317 (47.4) 59.7 
Hospital 190 (28.4) 35.8 
Independent research institute 66 (9.9) 12.4 
Cooperative 
group/consortium 
29 (4.3) 5.5 
Non-government organization 18 (2.7) 3.4 
Government 17 (2.5) 3.2 
Industry  8 (1.2) 1.5 
Not applicable 2 (0.3) 0.4 
Other 6 (0.9) 1.1 
Missing 16 (2.4) 2.9 
Number of health 
professionals’ part of the 
clinical study team 
0 4 (0.7)  
1 170 (31.1)  
2 162 (29.6)  
3 110 (20.1)  
>4 78 (14.3)  
Missing  23 (4.2)  
Study type Intervention (clinical trial) 451 (82.4)  
Observation  80 (14.6)  
Missing  16 (2.9)  
 Intervention typec Treatment 314 (69.6)  
Prevention 83 (18.4)  
Quality of life 20 (3.7)  
Screening 12 (2.7)  
Epidemiological 8 (1.8)  
Diagnostic  8 (1.8)  
Genetic 1 (0.2)  
Missing  5 (1.1)  
Phase type Phase 0 (Exploratory) 51 (9.3)  
Phase I 67 (12.2)  
Phase II 92 (16.8)  
Phase III 94 (17.2)  
Phase IV  69 (12.6)  
Don’t know  10 (1.8)  
Not applicable  144 (26.3)  
Missing  20 (3.7)  
Number of clinical study 
trial sites  
1 296 (54.1)  
2-4 116 (21.2)  
5-9 46 (8.4)  
10-19 32 (5.9)  
>20 39 (7.1)  
Missing  18 (3.3)  
 Multi-site studies being 
part of an international 
studyd 
Yes  53 (22.7)  
No  179 (76.8)  
Missing 1 (0.4)  
Data collection settinga,e Hospital 321 (48.8) 60.9 
University  83 (12.6) 15.7 
Private practice 49 (7.4) 9.3 
Health centre 48 (7.3) 9.1 
 
 
Independent research institute  46 (7.0) 8.7 
In-home care 23 (3.5) 4.4 
Other  68 (10.3 12.9 
Missing  20 (3.0) 3.7 
Participants targeted for 
baseline enrolment 
<20 49 (9.0)  
20-99 192 (35.1)  
100-499 203 (37.1)  
>500 82 (15.0)  
Missing  21 (3.8)  
Employ a data monitor or 
data manager 
Yes 250 (45.7)  
No 255 (46.6)  
Not applicable 17 (3.1)  
Don’t know 6 (1.1)  
Missing  19 (3.5)  
a Multiple response question (select all that apply) 
b Total n (%) =669 (100.0) 
c Intervention type, n=451. 
d Part of an international study, n=233. 
e Total n (%) =658 (100.0) 
 
Table 3 shows survey responses regarding data definition, collection, processing and representation, 
and education and training on data quality. The majority of respondents (366, 66.9%) reported that 
the clinical study followed national and/or international regulations, guidelines and/or standards 
(Table 3). Of those who responded ‘yes’ and ‘don’t know’1, n=422 (77.1%) to following 
regulations, guidelines and/or standards the National Statement on Ethical Conduct and Research 
(86.0%) was most commonly used. This was followed by the Good Clinical Practice (GCP) 
guideline (54.5%) and the Australian Clinical Trials Handbook (33.6%) (Supplementary data 1). 
The most common (46.4%) response to the question about the recording medium for source data 
was a single data capture instrument. The major recording instrument was paper (77.0%) and least 
was mobile or tablet application (10.4%) (Supplementary data 2). Just under half (46.4%) of the 
respondents reported not using any clinical data management software to store data. Of those who 
did (35.3%), the majority (93.3%) utilised a single application (93.3%) (Table 3); REDCap data 
management software was most common (17.6%) (Supplementary data 2). At the time of the 
survey, 418 (76.4%) respondents answered that more than one monitoring method was applied to 
the clinical study. With statistical techniques (64.5%), logic, range and consistency checks (63.6%) 
and source data verification (SDV) (55.0%) most commonly applied to audit and monitor data. 
Only 48 (8.8%) of respondents reported a set error acceptance level; of which 28 (58.3%) reported 
the level ranging from 0-10% (mean 4.6 ± 2.8 SD). Further, only 72 (13.2%) clinical studies 
reported generating data quality and consistency reports. The personnel responsible for reviewing 
these reports varied, ranging from the chief investigator (63.9%), senior staff management (50.0%) 
 
1 Survey respondents who selected ‘don’t know’ were also presented with the same list of regulations, guidelines and/or 
standards as those selected ‘Yes’.  
 
 
and data entry staff (43.1%) (Supplementary data 3). In total, two-thirds (66.7%) of respondents 
answered that more than one person reviewed these reports. Less than half of the respondents 
answered that training and/or development devoted to data quality was provided to the primary 
person(s) responsible for data entry (240, 43.9%) and data monitoring (205, 37.5%) (Table 3). The 
most common training component for both data entry staff (79.1%) and data monitors (80.8%) was 
in protocol procedures (Supplementary data 4). Similarly, respondents answered that training in 
more than one area was received by data entry (205, 85.4%) and data monitoring (176, 85.9%) staff.  
 
 















Data dictionary   
Does the clinical study…  
 have a data dictionary? 262 (47.9) 190 (34.7) 44 (8.0) 23 (4.2) 28 (5.1) 
 involve staff in developing CRFs? 289 (52.8) 135 (24.7) 76 (13.9) 18 (3.3) 29 (5.3) 
 have a definition for protocol 
deviation and/or violation? 
349 (63.8) 117 (21.4) 42 (7.7) 9 (1.6) 30 (5.5) 
 have a data quality monitoring plan 
or SOP for quality assurance and 
quality control? 
343 (62.7) 136 (24.9) 22 (4.0) 13 (2.4) 33 (6.0) 
 outsource data monitoring to another 
company?  
27 (4.9) 454 (83.0) 27 (4.9) 5 (0.9) 34 (6.2) 
 follow national and international 
regulations, guidelines and/or 
standards for data monitoring?  
366 (66.9) 59 (10.8) 34 (6.2) 56 (10.2) 32 (5.9) 
Data collection and storage 
Does the clinical study… 
 have a standard operating procedure 
specifically for data collection? 
399 (72.9) 85 (15.5) 10 (18.) 10 (1.8) 43 (7.9) 
 implement procedures to overcome 
missing values in the process of data 
collection? 
242 (44.2) 153 (28.0) 60 (11.0) 49 (9.0) 43 (7.9) 
Number of data capture instruments used to record source data? 
 1  254 (46.4)     
 2 149 (27.2)     
 3 68 (12.4)     
 4+ 37 (6.8)     
 Missing  39 (7.1)     
Does the clinical study use a clinical 
data management tool to store data? 
193 (35.3) 254 (46.4) 26 (4.8) 22 (4.0) 52 (9.5) 
 Number of tools used to store data?a 
  1 180 (93.3)     
  2 13 (2.4)     
  Missing  0 (0)     
Data processing  
Does the research team of the clinical study complete any of the following data monitoring procedures?  
 Statistical techniques  353 (64.5) 69 (12.6) 29 (5.3) 20 (3.7) 76 (13.9) 
 Logic, range and consistency checks 348 (63.6) 77 (14.1) 37 (6.8) 18 (3.3) 67 (12.2) 
 Source data verification 301 (55.0) 105 (19.2) 48 (8.8) 23 (4.2) 70 (12.8) 
 Onsite monitoring 259 (47.3) 148 (27.1) 46 (8.4) 20 (3.7) 74 (13.5) 
 Double data entry 190 (34.7) 224 (41.0) 43 (7.9) 17 (3.1) 73 (13.3) 
 Centralised monitoring 150 (27.4) 200 (36.6) 87 (15.9) 24 (4.4) 86 (15.7) 
 Remote monitoring 86 (15.7) 258 (47.2) 98 (17.9) 17 (3.1) 88 (16.1) 
 Risked-based targeted monitoring 58 (10.6) 247 (45.2) 102 (18.6) 50 (9.1) 90 (16.5) 
 Risked-based triggered monitoring 56 (10.2) 244 (44.6) 106 (19.4) 50 (9.1) 91 (16.6) 
 Other  9 (1.6) 141 (25.8) 88 (16.1) 31 (5.7) 278 (50.8) 
Data representation  
Does the clinical study… 
 have an error acceptance level?  48 (8.8) 222 (40.6) 92 (16.8) 94 (17.2) 91 (16.6) 
 
 
  If yes, and the error rate is found 
to be higher than the approved 
acceptance level, does your 
organisation implement further 
follow-up monitoring?b 
25 (52.1) 7 (14.6) 11 (22.9) 2 (4.2) 3 (6.3) 
 have a standard equation and/or 
method used to calculate error? 
50 (9.1) 219 (40.0) 88 (16.1) 89 (16.3) 101 (18.5) 
 have data quality and consistency 
reports generated?  
72 (13.2) 229 (41.9) 78 (14.3) 67 (12.2) 101 (18.5) 
 have a feedback mechanism in place 
to ensure continuous quality 
improvement?  
99 (18.1) 209 (38.2) 73 (13.3) 61 (11.2) 105 (19.2) 
Education and training 
Is it required that the primary person(s) responsible for data entry have… 
 achieved a minimum level of 
education 
269 (49.2) 113 (20.7) 49 (9.0) 18 (3.3) 98 (17.9) 
 a minimum level of experience 207 (37.8) 164 (30.0) 54 (9.9) 21 (3.8) 101 (18.5) 
 training/development devoted to data 
quality 
240 (43.9) 135 (24.7) 57 (10.4) 15 (2.7) 100 (18.3) 
Is it required that the primary person(s) responsible for monitoring the data have… 
 achieved a minimum level of 
education 
268 (49.0) 68 (12.4) 66 (12.1) 34 (6.2) 111 (20.3) 
 a minimum level of experience 209 (38.2) 114 (20.8) 74 (13.5) 37 (6.8) 113 (20.7) 
 training/development devoted to data 
quality 
205 (37.5) 122 (22.3) 72 (13.2) 33 (6.0) 115 (21.0) 
Are the skills and performance of the 
person(s) in charge of data monitoring 
assessed via periodic onsite evaluations 
by a third party (e.g. manager) during 
monitoring visits? 
72 (13.2) 243 (44.4) 76 (13.9) 40 (7.3) 116 (21.2) 
a Number of applications used to store data, n=193 
b The total number of answers for this question is n=48.  
Abbreviations: CRF, Case report form; SOP, Standard operating procedure 
Statistical techniques: For example, cluster and outlier analyses.  
Logic, range and consistency checks: Flag indicator results that fail common-sense comparisons to other indicators or 
other disaggregation. 
Source data verification: Comparing source data (original or certified copy) documents to data recorded or entered to a 
case report form or electronic record or database. 
Onsite monitoring: All monitoring activities undertaken at the clinical trial site. 
Double data entry: Entering the data twice and comparing differences between datasets 
Centralised monitoring: Data collected through an electronic data capture and queries identified by monitor that may 
need further attention to alleviate problems. 
Remote monitoring: Data monitored off-site, includes delivering documents via email, fax or snail mail to monitoring 
personnel to conduct source data verification. 
Risked-based targeted monitoring: Focus on certain data points that have been identified to have the most risk.  
Risked-based triggered monitoring: After certain events like a large number of adverse events or deviations occur this 
leads to more detailed monitoring. 
 
 
After deletion of 368 cases with missing values, data from 179 clinical studies were available for 
regression analysis. 155 clinical studies (86.6%) were classified as an intervention trial. A test of the 
full regression model using the forced entry with all 13 predictors against a constant-only model 
was not significant, χ2 (13, 179) = 15.827, p=0.259 (Table 4). Multivariate analysis demonstrated 
that having a definition for a protocol deviation and/or violation (odds 3.065, p=0.096) was 
borderline significant and positively associated with intervention (clinical) trials. None of the other 
covariates had a significant association with clinical study classification. The forced entry model 
correctly classified the outcome for 87.2% of the cases. Both the forwards χ2 (1, 179) = 3.797, 
p=0.051 (Supplementary data 5) and backwards stepwise χ2 (5, 179) = 9.997, p=0.075 
(Supplementary data 6) models bordered on significance. However, both models demonstrated that 
having a definition for a protocol deviation and/or violation (forward stepwise odds 2.433, p<0.05) 
(backward stepwise odds 2.640, p<0.05) had significant, positive association with intervention trial. 
The forwards and backwards stepwise models both correctly classified the outcome for 86.6% of 
the cases. A higher Nagelkerke R square indicates that the forced entry model (0.155) was a better 
model fit, in comparison to the forwards stepwise (0.038) and the backwards stepwise (0.100) 
models.    
 
 
Table 4: Forced entry method, coefficients of the model predicting whether a clinical study was observational or interventional (dependent variable) 
based on n=179 (32.7%). 
Category Variable  Univariable analysis Multivariate analysis 
      95% CI  
  





Lower  Upper  P 
Clinical study 
demographics 
Phase of study (4, 373) = 52.930 0.000 a       
Trial sitesb  (2, 529) = 1.760 0.415       
Participants targeted for baseline enrolmentc (3, 526) = 5.028 0.170       
 Participants at baseline P1#    -0.405 0.216 0.667 0.121 3.687 0.642 
 Participants at baseline P2#    0.508 0.322 1.663 0.287 9.633 0.571 
 Participants at baseline P3#   0.120 0.000 1.012 0.125 8.193 0.991 
Data monitor  (1, 505) = 0.027 0.870       
Data collection 
setting  
Health centre (1, 527) = 0.222 0.638       
Hospital (1, 527) = 9.859 0.002 0.185 0.099 1.204 0.379 3.821 0.753 
Independent institute (1, 527) = 0.618 0.432       
In home care (1, 527) = 0.711 0.399a       
Private practice (1, 527) = 0.905 0.341       
University  (1, 527) = 9.776 
0.002 1.719 2.352 5.581 0.620 50.24
8 
0.125 
Other (1, 527) = 8.708 
0.003 1.426 1.515 4.161 0.430 40.27
6 
0.218 
Study set up  
Data dictionary  (1, 452) = 0.002 0.968       
Develop CRFs (2, 500) = 0.906 0.636       
Definition protocol deviation and/or violation  (1, 466) = 3.950 
0.047 1.120 2.773 3.065 0.820 11.45
8 
0.096 
Data quality monitoring plan/SOP QA and QC  (1, 479) = 2.437 0.119 0.452 0.438 1.571 0.412 5.987 0.508 
Outsource data monitoring (1, 481) = 5.118 0.024a       
Follow guidelines/regulations  (1, 467) = 3.031 0.082 -0.293 0.198 0.746 0.206 2.706 0.656 
SOP for data collection  (1, 484) = 0.625 0.429       
Overcome missing values  (1, 395) = 0.960 0.327       
Data collection 
and storage 
Data capture instruments to record source datad  (3, 508) = 3.751 0.290       





Logic, range and consistency checks  (1, 425) = 0.029 0.865       
Double data entry  (1, 414) = 0.040 0.841       
Statistical techniques  (1, 422) = 0.394 0.530       
Risk-based targeted monitoring  (1, 305) = 0.144 0.705       
Risk-based triggered monitoring  (1, 300) = 3.114  0.078 0.209 0.066 1.233 0.251 6.063 0.797 
Remote monitoring  (1, 344) = 2.372 0.123 -0.239 0.121 0.788 0.205 3.027 0.728 
Centralised monitoring  (1, 350) = 1.535 0.215       
Onsite monitoring  (1, 407) = 1.358 0.244       
Source data verification   (1, 406) = 2.294 0.130 -0.426 0.542 0.653 0.210 2.030 0.462 
Data 
representation  
Error acceptance level  (1, 270) = 0.876 0.349       
Standard equation/method to calculate error  (1, 269) = 0.023 0.880       
Generate data quality and consistency reports  (1, 301) = 0.718 0.397       
A feedback mechanism CQI  (1, 308) = 2.365 0.124 -0.567 0.901 0.567 0.176 1.829 0.342 
R2 = .911 (Hosmer & Lemeshow) .085 (Cox & Snell) .155 (Nagelkerke). Model χ2 (13, 179) = 15.827, p=0.259. Correctly classified 87.2% of the cases.  
Abbreviations: CI, confidence interval; CQI, continuous quality improvement; SOP, Standard Operating Procedure; QA, quality assurance; QC, quality control. 
* χ2 (df, n)  
a 1 cell has an expected count less than 5, therefore excluded. 
b Category of trial sites: 1 site, n=296; 2-4 sites, n=116; >5 sites, n=117. 
c Category by number of participants enrolled in baseline study: <20 participants, n=49; 20-99 participants, n=192; 100-499 participants, n=203; >500 participants, n=82. 
d Number of data capture instruments to record source data category: 1 instrument, n=254; 2 instruments, n=149; 3 instruments, n=68 4+ instruments, n=37.  
Participants at baseline uses <20 participants as the referent category. #Participants at baseline P1 (20-99), P2 (100-499), P3 (>500). All other variables are compared with ‘no’ as the 
referent category.  
Independent variables included in multivariate analysis: clinical study demographics (Participants targeted for baseline enrolment); data collection setting (hospital, university and 
other); study set-up (definition for a protocol deviation and/or violation, data quality monitoring plan/SOP QA and QC and follow guidelines/regulations); Data monitoring methods 




In this Australian national survey, we found that clinical studies implemented various procedures to 
ensure data quality; however, not all clinical studies followed International or National guidelines to 
ensure data integrity. A borderline association between the data quality monitoring variable, a 
definition for protocol deviation and/or violation and intervention trials, may suggest that clinical 
studies were more likely to implement the required procedures when they were provided with 
additional guidance and resources. Additionally, we saw that technology has modified study 
processes in data collection and storage, and implementing ‘new’ monitoring methods. Although 
smaller, single-site clinical studies, are yet to adopt technology. These observations suggest that 
further education and training are required to implement standardised procedures to guide data 
quality in smaller-scale clinical studies. 
 
Approximately 50% of the survey respondents were not following GCP guidelines for monitoring 
data quality. This may suggest that GCP may not be explicit enough to ensure data integrity is 
followed in all clinical research settings. As the GCP guidelines were written predominantly for 
drug intervention trials[40, 41], there might be limitation for their applicability to all clinical 
studies. Another reason might be that the majority of survey respondents were from smaller, single-
site research studies with limited resources. This suggests that GCP needs to provide more 
accessible information that are tailored for the needs of all clinical research studies including non-
drug intervention trials, cohort and observational studies.  
 
Further, this study identified that GCP training was only provided to 45% of data entry staff and 
51% of the primary person(s) responsible for monitoring data quality. This number is far behind the 
recommendation of a recent working group who concluded GCP training should be provided to all 
study personal engaged in the design, conduct, performance, monitoring, auditing, recording, 
analysis or reporting of a clinical trial2 [42]. Despite this recommendation, there was a strong 
consensus that GCP training lacks relevance to behavioural intervention studies, which may also 
explain the observed low GCP training rate for those single site, non-drug intervention trials in this 
study. Another explanation may be that in Australia it is recommended if there is inconsistency 
between GCP and the National Statement on Ethical Conduct in Human Research (National 
Statement), the National statement takes precedence[43].  
 
 
2 Clinical trial as defined by the National institute of Health (NIH): A research study in which one or more human 
subject are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate 
the effects of those interventions on health-related biomedical or behavioural outcomes.   
 
 
With additional guidance and resources, it appears that clinical studies are more likely to implement 
the required procedures. This observation is supported by the borderline association (forced entry) 
between a definition for protocol deviation and/or violation and intervention trials. This is further 
supported by both of the stepwise models demonstrating that having a definition for a protocol 
deviation and/or violation had a significant, positive association with the intervention trial. This 
association was found in all three models and may result from a level of compliance with the 
CONSORT statement that recommends reporting protocol violations[44, 45] and the National 
Statement which recognises that sponsors, investigators/researchers, institutions and Human 
Research Ethics Committees (HRECs) all have responsibilities to monitor clinical trials[46]. 
Further, supplementary guidance is provided in a reporting framework for protocol deviations3, 
‘Reporting of Serious Breaches of Good Clinical Practice (GCP) or the Protocol for Trials 
Involving Therapeutic Goods’ which provides definitions, reporting procedures and timeframe, 
deviation examples, form templates and general question and answers[47]. Supplementary guidance 
has been provided for protocol deviations, which may explain the reason for the association, albeit 
the limited compliance with other areas related to monitoring the quality of clinical studies. For 
example, a review of 80 clinical trials found that protocol deviations are underreported and larger 
clinical trials (larger number of patients, sites, longer duration, complex management structure) 
were more likely to report protocol deviations than smaller clinical trials[48]. These findings may 
suggest that larger trials have better management and improved facilities, thus are more likely to 
report protocol deviations and/or violations. The findings of the review and the current study both 
suggest that when greater guidance and resources are provided, clinical studies are more likely to 
implement necessary procedures to ensure accurate, reliable and credible data. Therefore, we 
advocate eliminating disparity in resources and providing clinical studies in all size and study type 
with equal access to freely available standard procedures and clear frameworks. One such data 
quality monitoring framework (DQMF) that provides additional guidance and resources has been 
proposed by our study team, which is reported elsewhere[49]. In brief, the DQFM was developed 
from a small feasibility study (n=20)[5] and draws on the published literature, disregarding 
procedures widely applied first-hand in clinical studies. The DQMF requires further development 
and empirical testing before it can be recommended for future adaptation and use in clinical studies. 
The findings of this national survey are a key step in further developing the DQMF by identifying 
common and practical data collection processes, data processing and handling tools and procedures 
implemented in clinical research studies. 
 
3 The term deviation (recommended by ICH E3 – Structure and Content of the Clinical Study Report 2012) has been 
used to describe any breach, divergence or departure from the requirement of Good Clinical Practice or the clinical trial 




Although technology plays a key role in improving processes and efficiency in clinical studies, 
smaller, single-site clinical studies are yet to adopt technology, as 46% of the respondents in this 
survey reported they do not use data management software. A possible explanation for this is that 
small, single-site studies find it difficult to afford expensive and sophisticated technology despite 
the potential benefit of facilitating critical-decision making procedures[50]. This is in line with the 
literature that reported due to the limitation of time and resources, not all research trials implement 
the necessary data quality management tools and procedures[16]. Further, evidence suggests that 
the adoption of e-technology (digital and electronic technology that utilizes mobile devices or the 
Internet) into the design of clinical research studies has been relatively slow due to limited 
empirical evidence to support the benefits of such technology in improving study design and 
results[51]. Instead, this study revealed clinical studies implemented ‘traditional methods’ which 
included paper data capture and SDV. In accordance with this finding, a previous Canadian survey 
also reported that 59% of the clinical trials used paper CRFs and reported advantages such as quick 
to implement, simple and convenient[52]. It is clear that traditional methods implemented to collect 
and monitor data are still being used despite updated published evidence that promotes ‘new’ 
methods which compliment trial procedures by improving the resources available[53-55]. The 
results of this survey need to be interpreted with caution as we did not specifically ask respondents 
to point out the difference between automatic and manual data capture to record study events. With 
automatic capture a machine reads the paper which may reduce the amount of overall error in 
clinical studies. Currently, there is lack of coherent guidance and standard “good practices” in 
clinical research. Paper data collection and transcription of data into an electronic system are more 
likely to introduce avenues for error, is a costly and an onerous procedure[56]. Similarly, two 
reviews on monitoring methods, found SDV to be time consuming, expensive and does not 
guarantee error free results[53, 57]. To overcome this issue standard procedures and education are 
needed on the benefits of incorporating technology into clinical studies to improve research 
outcomes.  
 
There are several limitations in this study. First, the majority of responders were from small, single-
site academic studies, causing limitation on representativeness of the results for the broader research 
community including substantial number of multi-site international clinical trials. An additional 
restriction is that our survey respondents were all associated to clinical studies listed on the 
ANZCTR database as ‘recruiting' or ‘active, not recruiting’, in which the ANZCTR accounts for 
approximately 60% of registered clinical studies in Australia [58]. Another limitation is that the 
respondents were identified from a Clinical Trials Registry by Australian postal address. The same 
 
 
contact person could be contacted repeatedly due to being listed more than once via multiple 
associations with the Registry. This could have a negative or positive impact on response rates. 
Survey results are subject to potential bias in a positive direction as the respondents who completed 
the survey may be more knowledgeable about data quality monitoring measures and procedures 
than those who were non-respondents. Furthermore, the number of non-respondents might be due to 
confidentiality considerations[59]. Although we attempted to calculate the total number of ‘return to 
sender’ letters and bounced emails, these numbers should be considered with caution. It should be 
highlighted that throughout this research we have referred to clinical research as it is mostly 
concerned with prospective clinical studies, though we note that clinical studies may also include 
retrospective observational studies. While we did ask respondents about the study type, we did not 
explicitly ask them about their study designs. We did not attempt to sample evenly by clinical study 
type and, therefore, our results sway towards 83% of respondents reporting for an intervention trial. 
However, this figure is similar with the national figure of, 86% of registered clinical studies were 
intervention trials between 2006 – 15[58]. Thus, the results of our study may be considered 
representative of Australian clinical studies. The logistic regression output should be interpreted 
with caution as it was derived from a limited 24 observational studies that were included in the 
analysis. Finally, as with any survey, the results are subject to recall bias. 
 
Our findings enable us to make recommendations for future research. First, understanding the 
reason why clinical studies are not following national and international guidelines using qualitative 
methods. Secondly, further guidance is warranted to provide detailed frameworks which include 
resources for clinical study monitoring best practice. Thirdly, the use of technology to improve 
study procedures needs more empirical evidence to guide clinical researcher choice in overcoming 
challenges related to data collection, monitoring and upholding quality.  
 
The evidence of this study enables us to hypothesise the reasons and challenges as to why smaller, 
single-site clinical studies are not using current guidance and technology for data monitoring. We 
speculate that the major challenges are limited resources, facilities, management and funding. As 
suggested by Eisenstein et al.[60] the financial cost of monitoring site data is estimated to represent 
25-30% of the total study costs. This evaluation is based on two randomised phase III multinational 
drug trials which called for >14000 patients. Therefore, a different evaluation for small single-site 
clinical studies is required and may result in different percentage costs. One consideration for small 
scale clinical studies is to use freely available electronic software or web-based applications for data 
capture and management. The two primary data management tools used by our survey respondents 
were REDCap[27] and OpenClinica (www.OpenClinica.com). Both of these tools provide easy to 
 
 
use electronic data capture (EDC) systems with built-in data validation (logic, range and 
consistency checks), data tracking (audit trails), automated export procedures for statistical analysis 
and the availability to import data from external sources. There are multiple alternative EDC 
systems that are not named here. However, clinical researchers need to consider the additional costs 
that the freely available open source software may incur with regard to staff training, maintenance, 
support and hardware to operate the system. We suggest researchers evaluate the available software 
options and compare them with their intended goals and requirements to make an informed decision 
as to which software system is most suitable for their study.  
 
From our findings we also suggest that clinical studies develop a data management plan, a risk and 
safety management plan and a monitoring plan as previous research suggests that data management 
plans are not necessarily utilised in all cases due to reasons that include sponsor requirements and 
monetary constraints[5, 9, 50]. The monitoring plan should explicitly define the approach for data 
definition, collection, processing and handling, and clearly describe the education and training 
related to data quality that staff undertake. Sharing these plans between small, single-site academic 
studies will enable knowledge sharing between clinical study sites and provide additional guidance 
on any challenges or reasons why procedures worked or did not work. This could be supported by 
an online standardised platform which provides generic and baseline templates which are available 
for download by clinical researchers, to share and integrate procedures efficiently between 
organisations and groups. Though current practice suggests that research groups may not be willing 
to share their data quality procedures as they may be considered confidential by many 
organisations[59]. To provide greater motivation to developing data management plans as core to 
clinical research, the use of incentives (e.g. career development and training) may be used as a 
strategy to improve staff self-awareness and engagement in their commitment to maintaining data 
quality[61]. Finally, until a more suitable education and training course for non-drug intervention 
trials is developed, we recommend that all clinical studies complete the GCP education and training 
as it remains the international ‘gold standard’. 
 
5. Conclusion 
In summary, we found that not all Australian clinical studies follow the GCP guidelines and the 
majority of study personnel do not receive GCP training. Instead, small, single-site academic 
clinical studies implement various non-standardised ad hoc measures and procedures to ensure data 
quality. When provided with additional guidance, resources and frameworks, clinical studies were 
more likely to implement the necessary procedures. Small, single-site academic studies are yet to 
adopt technology to replace their use of traditional methods to collect and monitoring data, which 
 
 
are costly and burdensome. In order to improve standardisation of clinical trials, education and 
training needs to be provided and accessible to all researchers in all types of clinical studies, large 
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Figure legends  
Figure 1 – Survey invitation flow diagram.  
 
Table legends  
Table 1 – Survey respondents demographic characteristics (n=547). 
Table 2 – Survey respondents associated clinical study demographic characteristics (n=547). 
Table 3 – Data quality monitoring, education and training on data quality (n=547). 
Table 4 – Forced entry method, coefficients of the model predicting whether a clinical study was 
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Supplementary data 1 
 
Table 1: Combined ‘Yes’ and ‘Don’t know’ responses for national and international regulations, 





Which of the following regulations, guidelines and/or standards are followed.a,b 
 National Statement on Ethical Conduct and Research 363 (40.2) 86.0 
 Good Clinical Practice Guidelines (GCP) - International 
Conference for Harmonisation 
230 (25.4) 54.5 
 The Australian Clinical Trial Handbook - Therapeutic Goods 
Administration (TGA) 
142 (15.7) 33.6 
 International classification of diseases (ICD) 41 (4.5) 9.7 
 International Standards Organisation (ISO) quality systems 
standard 
24 (2.7) 5.7 
 Food and Drug Authority (FDA) 21 CRF part 11 12 (1.3) 2.8 
 Systematized Nomenclature of Medicine -- Clinical Terms 
(SNOMED-CT) 
11 (1.2) 2.6 
 Clinical data acquisition standards harmonization (CDASH) 10 (1.1) 2.4 
 Food and Drug Authority (FDA) Monitoring of Clinical 
Investigations 
8 (0.9) 1.9 
 Operational Data Model (ODM) 6 (0.7) 1.4 
 Analysis Data Model (ADaM) 3 (0.3) 0.7 
 Study data tabulation model implementation guide for human 
clinical trials (SDTM) 
2 (0.2) 0.5 
 Health Level 7 (HL7) 1 (0.1) 0.2 
 Logical Observation Identifiers names and Codes (LOINC) 1 (0.1) 0.2 
 Other 23 (2.5) 5.5 
 Don’t know  22 (2.4) 5.2 
 Missing  4 (0.4) 0.9 
a Multiple response question (select all that apply) 





Supplementary data 2 
 
Table 1: Data collection and storage tools (n=547) 
Variable n (%) Percent of 
Cases (%) 
Which data capture instruments are used to record source data?a,b 
 Paper 391 (41.2) 77.0 
 Microsoft excel spreadsheet/workbook 140 (14.7) 27.6 
 Database management software /tool 114 (12.0) 22.4 
 Electronic case report form (eCRF) 91 (9.6) 17.9 
 Automated instrument  
(e.g. pathology, ultrasound, x-ray) 
84 (8.8) 16.5 
 Mobile or tablet application  53 (5.6) 10.4 
 Don’t know 3 (0.3) 0.6 
 Other  35 (3.7) 6.9 
 Missing  39 (4.1) 7.1 
Are any of the following clinical data management tools used to store data?a,c 
 Noned 256 (45.7) 51.7 
 REDCap 87 (15.5) 17.6 
 OpenClinica 13 (2.3) 2.6 
 RAVE 6 (1.1) 1.2 
 ORACLE CLINICAL 4 (0.7) 0.8 
 MACRO 1 (0.2) 0.2 
 Not applicable 26 (4.6) 5.3 
 Don’t know 22 (3.9)  4.4 
 Other  93 (16.6) 18.8 
 Missing  52 (9.3) 9.5 
a Multiple response question (select all that apply) 
b Total n (%)=950 (100.0) 
c Total n (%)=560 (100.0) 
d n=2 respondents answered ‘no’ and ‘not applicable’ due to select all apply survey item. Responses 
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Who reviews the reports of data quality and consistency?a,b 
 Chief investigator 46 (31.1) 63.9 
 Senior staff management 36 (24.3) 50.0 
 Data entry staff 31 (20.9) 43.1 
 Auditor/Monitor 15 (10.1) 20.8 
 Sponsor  9 (6.1) 12.5 
 Other  11 (7.4) 15.3 
 Missing  0 (0) 0 
a Multiple response question (select all that apply) 
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Table 1: Follow-up questions for education and training data entry staff (n=240) and data monitor 
(n=205). 
Is it required that the primary person(s) responsible for data entry have training/development 
devoted to data quality. 
 If yes, which of the following areas are data entry staff 




  Protocol procedure 181 (22.2) 79.1 
  SOPs 150 (18.4) 63.0 
  skills development 136 (16.7) 57.1 
  specific research are investigation 116 (14.2) 48.7 
  Monitoring process 111 (13.6) 46.6 
  ICH-GCP 106 (13.0) 44.5  
  Don’t know  5 (0.6) 2.1 
  Other 9 (1.1) 3.8 
  Missing  2 (0.2) 0.8 




  one-on-one 175 (44.5) 74.5 
  Group 116 (29.5) 49.4 
  online/computer modules(s) 91 (23.2) 38.7 
  Other 6 (1.5) 2.6 
  Missing 5 (1.3) 2.1 




  Prior to research  199 (44.0) 85.0 
  Throughout 169 (37.4) 72.2 




  Other 4 (0.9) 1.7 
  Missing 6 (1.3) 2.5 
Is it required that the primary person(s) responsible for monitoring the data have 
training/development devoted to data quality.  
If yes, which of the following areas is this person provided training in:a,e 
 Protocol procedure 164 (20.6) 80.8 
 Monitoring process 152 (19.1) 74.9 
 skills development 127 (16.0) 62.2 
 SOPs 126 (15.8) 62.1 
 specific research are investigation 113 (14.2) 55.7 
 ICH-GCP 104 (13.1) 51.2 
 Don’t know  2 (0.3) 1.0 
 Other 5 (0.6) 2.5 
 Missing 2 (0.3) 1.0 
If yes, please specify how education and training is delivered:a,f 
 one-on-one 147 (41.5) 74.2 
 online/computer modules(s) 96 (27.1) 48.5 
 Group 94 (26.6) 47.5 
 Other 10 (2.8) 5.1 
 Missing 7 (2.0) 3.4 
If yes, please specify when education and training is delivered:a,g 
 Prior to research  168 (45.0) 83.6 
 
 
 Throughout 139 (37.3) 69.2 
 Triggered due to reoccurring event (e.g. incomplete CRFs) 57 (15.3) 28.4 
 Other 5 (1.3) 2.5 
 Missing 4 (1.1) 2.0 
a Multiple response question (select all that apply) 
b Total n (%)=816 (100.0) 
c Total n (%)=393 (100.0) 
d Total n (%)=452 (100.0) 
e Total n (%)=795 (100.0) 
f Total n (%)= 354 (100.0) 
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Table 1: Forward stepwise (step 1), coefficients of the model predicting whether a clinical study was observational or interventional (dependent 
variable) based on n=179 (32.7%). 
Category Variable  Multivariate analysis 






Lower  Upper  P 
Study set up Definition protocol deviation and/or violation 0.889 3.922 2.433 1.009 5.864 0.048 
R2 = .0 (Hosmer & Lemeshow) .021 (Cox & Snell) .038 (Nagelkerke). Model χ2 (1, 179) = 3.797, p=0.051. Correctly classified 86.6% of the cases. 
Abbreviations: CI, confidence interval. 
Definition for protocol deviation and/or violation is compared with ‘no’ as the referent category. 
Independent variables included in multivariate analysis: clinical study demographics (Participants targeted for baseline enrolment); data collection setting (hospital, university 
and other); study set-up (definition for a protocol deviation and/or violation, data quality monitoring plan/SOP QA and QC and follow guidelines/regulations); Data 
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Table 1: Backwards stepwise (step 9), coefficients of the model predicting whether a clinical study was observational or interventional 
(dependent variable) based on n=179 (32.7%). 
Category Variable  Multivariate analysis  






Lower  Upper  P 
Data collection 
setting 
University  1.674 2.511 5.332 0.673 42.264 0.113 
Other 1.472 1.943 4.356 0.550 34.503 0.163 
Study set up Definition protocol deviation and/or violation 0.971 4.469 2.640 1.073 6.495 0.035 
R2 = .417 (Hosmer & Lemeshow) .054 (Cox & Snell) .100 (Nagelkerke). Model χ2 (5, 179) = 9.997, p=0.075. Correctly classified 86.6% of the cases. 
Abbreviations: CI, confidence interval.  
All variables (university setting, other setting, definition for protocol deviation and/or violation) are compared with ‘no’ as the referent category.  
Independent variables included in multivariate analysis: clinical study demographics (Participants targeted for baseline enrolment); data collection setting (hospital, university 
and other); study set-up (definition for a protocol deviation and/or violation, data quality monitoring plan/SOP QA and QC and follow guidelines/regulations); Data 
monitoring methods (risk-based triggered monitoring, remote monitoring and source data verification); and data representation (a feedback mechanism CQI).  
 
 
